Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
11.5
Expiration
Nov 6, 2026
DTE
17d
Moneyness
OTM
Intrinsic
$0.00
IBRX 11.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.05 | -82.14% | 7 | 143 |
| Oct 30, 2026 | 10d | $0.10 | -82.14% | 72 | 769 |
| Nov 6, 2026 | 17d | $0.35 | -38.60% | 2 | 39 |
| Nov 13, 2026 | 24d | $0.65 | +22.64% | 22 | 25 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
IBRX Nearby Strikes · Nov 6, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 8.5 C | $2.20 | +37.50% | 4 | 20 | OTM |
| 9 C | $1.10 | -26.17% | 18 | 63 | OTM |
| 9.5 C | $0.70 | -48.91% | 22 | 45 | OTM |
| 10 C | $0.70 | -30.00% | 65 | 195 | OTM |
| 10.5 C | $0.65 | -14.47% | 4 | 44 | OTM |
| 11 C | $0.45 | -18.18% | 34 | 417 | OTM |
| 11.5 C | $0.35 | -38.60% | 2 | 39 | OTM |
| 12 C | $0.40 | -18.37% | 17 | 284 | OTM |
| 12.5 C | $0.10 | -74.36% | 1 | 22 | OTM |
| 13 C | $0.43 | +22.86% | 7 | 63 | OTM |
| 14 C | $0.22 | -56.00% | 100 | 145 | OTM |
| 15 C | $0.25 | +0.00% | 2 | 2 | OTM |
| 16 C | — | — | 0 | 0 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.